At Appeals Hearing, Myriad Outlines Stance on BRCA IP Rights for Whole-Genome Sequencing

For the first time, before three federal circuit judges, Myriad stated its position on whether whole-genome sequencing assays that include BRCA mutations would infringe its patents.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.